



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax. : 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Ref. No.: ADL/SE/2018-19

Date: 5th November, 2018

To,
Department of Corporate Service,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE CODE - 524348
BSE ID - AARTIDRUGS

To,
National Stock Exchange of India Limited,
"Exchange Plaza", Bandra - Kurla Complex,
Bandra (E), Mumbai - 400051.
NSE SYMBOL: AARTIDRUGS

Sub: Press Release for September, 2018

Dear Sir/Madam,

Please find enclosed herewith copy of the press release issued by the Company on 5th November, 2018.

This is for your information and records.

Thanking you,

Yours faithfully,
For Aarti Drugs Limited

V. S. Ranade

Vibhav S. Ranade

Company Secretary & Compliance Officer
ICSI M. No. A35284



Encl: A/A



Aarti Drugs Limited

Manufacturers of : Bulk Drugs & Chemicals

Corporate Office : Mahendra Industrial Estate,
Ground Floor, Plot No. 109-D, Road No. 29,
Sion (East), Mumbai - 400 022. (India)
Tel. : 022-2407 2249 / 2401 9025 (30 Lines)
Fax.: 022-2407 3462 / 2407 0144
Email: admin@aartidrugs.com
website: www.aartidrugs.com
CIN No.:L37060MH1984PLC055433

Press release for Sep'18:

In September quarter, the Company recorded the quarterly revenue of Rs. 347.51 Crores with Y-o-Y growth of 8.82%. Exports of the API segment grew approximately by around 19.88% and domestic sales by around 7.4%. However, the formulation segment revenues declined by 13.07%.

Consolidated EBITDA for the quarter ended Sep'18 is Rs. 47.09 Crores, down by 10.5% and Consolidated Profit after tax for the quarter ended Sep'18 is Rs. 18.05 Crores, down by 23.52%. Formulation segment profit was lower this quarter due to lower capacity utilization and lack of execution of export orders as compared to last year Sep'17 quarter. Disruption in supply of few key raw materials and change of processes for existing products have led to production shortages in API segment. This resulted in under absorption of overheads thus increasing manufacturing expenses for this quarter. The Company was able to pass on the increased raw material prices to its customers in absolute terms, however it resulted in decreased gross margins temporarily due to base effect. Once the prices stabilize, we expect the operating margins to restore to original levels. The Company was able to maintain its Debt/Equity ratio to 1.11 as on Sep'18 despite of increased working capital requirement.

The Company has recently submitted the voluntary response for the EIR pertaining to Dec'17 inspection, which was received recently. Company would be contacting USFDA for further course of action. The Company continues to focus on different therapeutic categories related to lifestyle related diseases for diversification and currently antibiotic contributes to around 35% of its total API segment revenues. The Company recently completed the expansion of one its key anti-fungal molecule.

For Aarti Drugs Limited

Adhish P. Patil
Chief Financial Officer

